| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.17 | 0.004 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.093 | 0.004 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.005 |